19:04 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Staphylococcus Cell culture studies suggest inhibiting adenosine kinase, DCK or SLC29A1 could help treat Staphylococcus aureus infection. Screening of a CRISPR single-guide RNA (sgRNA) library in a human lung lymphoblast cell line expressing CRISPR-associated protein...
20:45 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular; neurology

INDICATION: Atherosclerosis; stroke Mouse studies suggest inhibiting adenosine kinase could help treat atherosclerosis and stroke. In a mouse model of atherosclerosis, vascular endothelial cell-specific knockout of adenosine kinase decreased atherosclerotic lesion size and the necrotic area...
16:32 , May 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: B cell lymphoma; multiple myeloma (MM) Patient sample, cell culture and mouse studies identified a nucleoside analog that could help treat primary effusion lymphoma (PEL) and MM. High throughput screening of a small molecule library...
07:00 , Apr 17, 2014 |  BC Innovations  |  Cover Story

Contaminating cancer genomes

Two European teams have pinpointed the DNA-protective enzyme 7,8-dihydro-8-oxoguanine triphosphatase as a chemically tractable target whose inhibition kills cancer cells by accelerating DNA damage.1,2 Both groups have identified collections of small molecule inhibitors of the...
07:00 , Jul 30, 2012 |  BioCentury  |  Tools & Techniques

Screening beta

In the last 16 months Evotec AG has done two deals using its porcine beta cell screening technology. The first was a collaboration with Harvard University to discover diabetes therapies targeting beta cell regeneration. This...
07:00 , Jun 14, 2012 |  BC Innovations  |  Targets & Mechanisms

Beta testing adenosine receptor agonists

Researchers at the University of California, San Francisco have used a zebrafish screen to identify an adenosine receptor agonist that improved both b cell regeneration and glucose control in diabetic mice.1 The discovery could open...
07:00 , Mar 22, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Adenosine kinase Cell culture and rodent studies identified adenosine kinase inhibitors that could help treat...
08:00 , Mar 2, 1998 |  BC Week In Review  |  Clinical News

Metabasis regulatory update

Metabasis received notice of allowance for a U.S. patent covering a series of adenosine kinase inhibitors and their use to treat inflammation, pain and neurological diseases. Metabasis is a majority-owned subsidiary of Gensia...
07:00 , May 10, 1993 |  BC Week In Review  |  Clinical News

Gensia Pharmaceuticals Inc. data

Gensia Pharmaceuticals Inc.   Gensia Pharmaceuticals Inc. scientists presented data showing that two of its second-generation adenosine regulating agents, AKI-1 and AKI-2, had anti-inflammatory effects in two animal models of acute inflammation. The agents inhibit the...